EMEA receives 24th report of PML case linked with Tysabri

There has been a recent surge in new confirmed cases of progressive multifocal leukoencephalopathy (PML) associated with the multiple sclerosis drug, Tysabri (natalizumab), with the 24^th case reported to the EMEA on 25 October.